key: cord-0012864-m86a1ey9
authors: Du, Lei; Wang, Lei; Wang, Bo; Wang, Jin; Hao, Meng; Chen, Yi-bing; Li, Xi-zhi; Li, Yuan; Jiang, Yan-fei; Li, Cheng-cheng; Yang, Hao; Gu, Xiao-ke; Yin, Xiao-xing; Lu, Qian
title: A novel compound AB38b attenuates oxidative stress and ECM protein accumulation in kidneys of diabetic mice through modulation of Keap1/Nrf2 signaling
date: 2019-10-23
journal: Acta Pharmacol Sin
DOI: 10.1038/s41401-019-0297-6
sha: 3991da7a4ee8f6dd357e09435f59973ad46f84f6
doc_id: 12864
cord_uid: m86a1ey9

Extracellular matrix (ECM) deposition following reactive oxygen species (ROS) overproduction has a key role in diabetic nephropathy (DN), thus, antioxidant therapy is considered as a promising strategy for treating DN. Here, we investigated the therapeutic effects of AB38b, a novel synthetic α, β-unsaturated ketone compound, on the oxidative stress (OS) and ECM accumulation in type 2 diabetes mice, and tried to clarify the mechanisms underlying the effects in high glucose (HG, 30 mm)-treated mouse glomerular mesangial cells (GMCs). Type 2 diabetes model was established in mice with high-fat diet feeding combined with streptozocin intraperitoneal administration. The diabetic mice were then treated with AB38b (10, 20, 40 mg· kg(−1)· d(−1), ig) or a positive control drug resveratrol (40 mg· kg(−1)· d(−1), ig) for 8 weeks. We showed that administration of AB38b or resveratrol prevented the increases in malondialdehyde level, lactate dehydrogenase release, and laminin and type IV collagen deposition in the diabetic kidney. Simultaneously, AB38b or resveratrol markedly lowered the level of Keap1, accompanied by evident activation of Nrf2 signaling in the diabetic kidney. The underlying mechanisms of antioxidant effect of AB38b were explored in HG-treated mouse GMCs. AB38b (2.5−10 μM) or resveratrol (10 μM) significantly alleviated OS and ECM accumulation in HG-treated GMCs. Furthermore, AB38b or resveratrol treatment effectively activated Nrf2 signaling by inhibiting Keap1 expression without affecting the interaction between Keap1 and Nrf2. Besides, AB38b treatment effectively suppressed the ubiquitination of Nrf2. Taken together, this study demonstrates that AB38b ameliorates experimental DN through antioxidation and modulation of Keap1/Nrf2 signaling pathway.

Diabetic nephropathy (DN) is one of the most serious chronic complications of diabetes mellitus and affects~30% of type 2 diabetes mellitus patients [1] . It is characterized by glomerular mesangial cell proliferation, mesangial hypertrophy, and an accumulation of the extracellular matrix (ECM) [2] . The pathogenesis of DN remains unclear, and hemodynamic changes, genetic susceptibility, hyperglycemia, dyslipidemia, and oxidative stress (OS) have been seen as promoting factors for DN [3] . Among these, OS and its related reactions serve important roles in the progression of DN [4] . On one hand, excessive OS activates multiple intracellular signaling pathways, such as the JNK and PKC pathways, and stimulates transcription factors, such as nuclear factor NF-κB and AP-1, thus resulting in the increased deposition of the ECM [5] . On the other hand, the high expression of products with related activity directly leads to reduced matrix degradation, which results in glomerulosclerosis and renal fibrosis [6] .

The nuclear factor erythroid-derived 2-like 2 (Nrf2), as an important endogenous antioxidant transcription factor, protects cells from OS injury via interacting with antioxidant response element (ARE) [7] [8] [9] and then activates the transcription of downstream antioxidant enzymes, such as catalase (CAT), superoxide dismutase (SOD1 and SOD2), heme oxygenase-1 (HO-1), and NADPH quinone oxidoreductase (NQO-1) [10] [11] [12] . Kelch-like ECHassociated protein 1 (Keap1) has an important role in the Nrf2/ARE signaling pathway. In addition, Keap1-mediated Nrf2 ubiquitination and the phosphorylation of Nrf2 are the main regulators of Nrf2 [13] . Under basal conditions, Keap1, acting as an inhibitor, interacts with Nrf2 to form a complex to prevent the activation of Nrf2 by transcription [14] . However, in response to hyperglycemiamediated OS, Nrf2 is released from Keap1 and is transported into the nucleus, resulting in the activation of downstream antioxidant genes [15] [16] [17] . Therefore, targeting Nrf2 can effectively ameliorate OS in DN [8, 18, 19] .

According to basic mechanisms, several compounds with Nrf2 agonistic activity, such as sulforaphane and bardoxolone methyl, have been reported. Sulforaphane has been demonstrated to be beneficial for diabetic complications by promoting the nuclear accumulation of Nrf2 by changing the conformation of the cysteinyl residues of Keap1 [20] [21] [22] [23] . Bardoxolone methyl, which is derived from the natural product oleanolic acid, is an inducer of Nrf2 and was once seen as a promising new drug. However, a phase III clinical trial (BEACON) in patients with stage 4 CKD and type 2 diabetes was terminated because of its serious side effects, which are partly owing to the toxicity of the drug structure [17, 24] .

Hence, therapies targeting oxygen biology, such as those that modulate Nrf2, have been considered promising therapeutic methods for DN [25] . However, identifying high-efficiency and low-toxicity Nrf2 agonists is of great importance.

AB38b is a novel synthetic α, β-unsaturated carbonyl compound with biphenyl diester (DDB) as its precursor. α, βunsaturated carbonyl compounds, which act as Michael acceptors, have been found to covalently modify the cysteinyl residues of Keap1 to form covalent bonds and regulate related signaling pathways to have a role in disease prevention and treatment [26, 27] . Therefore, these α, β-unsaturated reactive ketones that function as chalcones are responsible for their biological activities. DDB is a synthetic intermediate of schisandrin C, a Chinese medicine herb used to treat hepatitis [28] . DDB has been reported to have various pharmacological effects, such as antiviral, antioxidant, immunomodulatory, and anticancer effects [29, 30] . Based on the evidence described above, a series of compounds containing these two structures, among which AB38b has shown excellent antioxidant activity and can activate Nrf2, have been designed and synthesized (Fig. 1e) . However, whether AB38b can alleviate DN and the specific mechanism needs to be further studied and clarified.

In the present study, we focused on whether AB38b can alleviate OS and ECM accumulation in DN by modulating the Keap1/Nrf2 signaling pathway.

AB38b (≥ 98% purity) was designed and synthesized by XiaoKe Gu (Xuzhou Medical University, Xuzhou, China) and was dissolved in dimethyl sulfoxide (DMSO) to generate a primary stock solution. The solution was stored at 4°C and then diluted in medium before each in vitro experimental study. For in vivo studies, AB38b was dissolved in a 0.5% carboxy methyl cellulose (CMC) solution.

Animal model Male C57BL/6 J mice weighing 20-25 g were obtained from the Laboratory Animal Centre of Xuzhou Medical University and the experiments were performed following the Guiding Principles for Care and Use of Laboratory Animals of Xuzhou Medical University.

To generate the animal model, normal mice that were fed chow and provided water ad libitum were injected with 0.1 mol/L sodium citrate buffer, pH 4.5. The normal mice were randomly divided into two groups (n = 9/group): the control group (N) and the high-dose group (N + AB38bH). The mice were intragastrically treated with 40 mg/kg AB38b dissolved in a 0.5% CMC solution daily. In the DN group, the mice were fed a high glucose (HG)-fat diet for 8 weeks and then injected intraperitoneally with streptozocin (100 mg/kg in 0.1 mol/L sodium citrate buffer, pH 4.5). Mice with fasting blood glucose (FBG) levels above 13.9 mmol/L were considered diabetic. DN mice were randomly divided into five groups (n = 9/group): the model group (DN), the low-dose group (10 mg/kg AB38b), the medium-dose group (20 mg/kg AB38b), the high-dose group (40 mg/kg AB38b) and the positive control groups (40 mg/kg resveratrol). A 0.5% CMC solution was used for the control and model groups, whereas different concentrations of Res and AB38b were administered orally to the appropriate groups. After 8 weeks, the mice were placed in metabolic cages for urine collection, and blood samples were also collected. The animals were killed, and the kidneys were removed rapidly. The kidneys were stored at −80°C for biochemical analysis.

Cell culture The mouse glomerular mesangial SV40-MES-13 cell line (Fuxiang Biotechnology Company, Shanghai, China, ATCC number CRL-1927) was cultured in Dulbecco's modified Eagle's medium (DMEM) containing 100 units/mL penicillin, 100 mg/mL streptomycin, and 10% fetal bovine serum. Confluent cells were cultured in serum-free DMEM media for 24 h before the experiments. The cells were divided into the normal group (NG, 5.56 mM), the vehicle control group (DMSO, 0.05%, D5879, Sigma, St. Louis, MO, USA), the HG group (HG, 30 mM, G7021, Sigma), the HG + lowdose AB38b group (AB38bL + HG, 2.5 μM), the HG + medium-dose AB38b group (AB38bM + HG, 5 μM), the high glucose + high-dose AB38b group (AB38bH + HG, 10 μM), the high glucose + resveratrol (5010, Sigma) positive control group (Res + HG, 10 μM), the sulforaphane positive control group (S4441, Sigma) and the MG132 positive control group (S2619, Selleckchem, Houston, TX, USA).

The mouse glomerular mesangial cells (GMCs) were cultured in 96well microplates at a density of 5000 cells/well. Twenty-four hours after cultivation, the cells were serum starved and treated with H 2 O 2 (400 μM, Beyotime Institute of Biotechnology, Nantong, China) and different concentrations of compounds. After exposure to the compounds for 24 h, a cytotoxicity assay was performed using a Cell Counting Kit-8 (Beyotime Institute of Biotechnology, Nantong, Jiangsu, China). The OD 450 nm , the absorbance value at 450 nm, was read using a 96-well plate reader (BioTek, Winooski, VT, USA), and the OD 450 nm absorbance was proportional to the viability of the cells.

Blood glucose was measured by test strips (The Johnson Laboratory, Las Vegas, NV, USA). Creatinine (Cr) and blood urea nitrogen (BUN) were determined using Cr and BUN assay kits. The levels of low-density lipoprotein cholesterol (LDL-C) and total cholesterol (T-CHO) were tested by assay kits (Jiancheng Bioengineering Institute, Nanjing, China).

Nuclear and cytoplasmic extraction The cytoplasmic and nuclear fractions were separated with extraction reagents (NE-PER, Thermo Scientific, Waltham, MA, USA). In brief, ice-cold CER I was added to the cell pellet, and the tube was vortexed vigorously at the highest setting for 15 s to fully suspend the cell pellet. Then, the tube was incubated on ice for 10 min. Ice-cold CER II was added to the tube, and the tube was vortexed for 5 s and incubated on ice for 1 min. The tube was vortexed for 5 s, followed by centrifugation at 12 000 r/min for 5 min to precipitate the nuclei. The supernatant (cytoplasmic extract) was immediately transferred to a clean prechilled tube. This tube was placed on ice until use or storage.

Western blotting analysis Homogenates of the glomeruli isolated from the renal cortex were prepared in lysis buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1 mmol/L ethylenediaminetetraacetic acid, 1% NP-40, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na 3 VO 4 and 20 mM NaF). The homogenates were incubated for 30 min at 4°C and centrifuged at 12 000 × g for 15 min at 4°C. SV40 cells were lysed in the lysis buffer described above and incubated at 4°C for 30 min. Then, the lysates were centrifuged at 12 000 × g for 15 min at 4°C. The protein concentrations were determined with a BCA Protein Assay Kit (Thermo Scientific) following the manufacturer's protocol. For immunoblotting, proteins (40-80 μg) were separated by 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). Then, the membranes were blocked in phosphate-buffered saline (PBS) containing 5% bovine serum albumin (BSA) for 2 h at room temperature and incubated with primary antibodies overnight at 4°C. Nrf2, Keap1, laminin, and collagen IV antibodies were purchased from Abcam (Cambridge, Cambridgeshire, UK). NQO-1, HO-1, and β-actin antibodies were obtained from Bioworld Technology (St. Louis, MO, USA). The first antibodies were detected using alkaline phosphatase-conjugated immunoglobulin G (Bioworld Technology) at room temperature for 1 h. The membranes were developed colorimetrically by a BCIP/NBT alkaline phosphatase color development kit (Beyotime Institute of Biotechnology). The density of the bands was quantified by densitometric analysis using ImageJ software from the National Institutes of Health.

RNA isolation and real-time quantitative reverse transcription polymerase chain reaction (qPCR) Total RNA was extracted with TRIZOL (Invitrogen, Carlsbad, CA, USA). The mRNA was reverse transcribed using an RT-Rever TraAce kit (Toyobo Co, Osaka, Japan). The cDNA was analyzed in duplicate reactions by qPCR using 0.2 mML gene-specific primers and 1 × LightCycler 480 SYBR green I Master (Roche Applied Science, Mannheim, Baden-Württemberg, Germany) in a total volume of 10 mL. qPCR was carried out in a LightCycler 480 (Roche Applied Science) using a thermal profile of 10 min at 95°C followed by 50 cycles of 15 s at 95°C, 30 s at 60°C, a melting curve of 15 s at 95°C, 60 s at 1 min, heating to 95°C and cooling for 30 s at 4°C. The results were analyzed using LightCycler 480 software (version 1.5, Roche Applied Science). The relative mRNA levels were analyzed using the ΔΔCt method. The primers (Sangon Biotech Corporation, Shanghai, China) used for gene amplification are listed in Table 1 .

In the experiment, the content of malondialdehyde (MDA) in the cells was analyzed on an high-performance liquid chromatography (HPLC) apparatus (Agilent, Santa Clara, CA, USA) according to a previously described method [31] . The analytical column was an Agilent Zorbax SB-C18 (250 mm × 4.6 mm; Agilent Technologies). The chromatographic conditions were as follows: mobile phase of 0.2% acetic acid in acetonitrile = 62: 38, column temperature: room temperature, injection volume: of 50 μL, detection wavelength of 310 nm, and flow rate of 1 mL/min. The concentrations of MDA were calculated from a standard curve prepared from 1,1,3,3-tetraethoxypropane. The MDA content in the renal cortex was measured spectrophotometrically using assay kits (JieMei Bioengineering Institute, Shanghai, China) performed according to the manufacturer's instructions.

LDH, SOD, GSH, and CAT activity The activities of lactate dehydrogenase (LDH), SOD, CAT, and the level of glutathione (GSH) in SV40 cells and the renal cortex were measured spectrophotometrically using assay kits (JieMei Bioengineering Institute) according to the manufacturer's instructions.

Immunoprecipitation (IP) analysis GMCs were lysed with IP buffer on ice for 30 min and centrifuged at 12 000 × g for 15 min at 4°C, and protein from the cell lysates was incubated with primary antibodies against Keap1 or Nrf2 at 4°C for 12 h. Immune complexes were captured with TrueBlot IP beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4°C for 4 h. After they were rinsed three times with IP lysis buffer, the bound proteins were boiled for 5 min and then eluted before Western blot analysis was performed. The protein bands were resolved and blotted with an anti-Keap1, anti-Nrf2 or antiubiquitin antibody at 4°C for 12 h.

Morphological analysis and IHC Kidney samples were fixed in 4% paraformaldehyde and embedded in paraffin. Sections that were 4-μm thick were cut for morphometric analysis and IHC. The sections were prepared for periodic acid-Schiff (PAS) and Sirius red staining, as described previously [32] . For immunohistological studies, immunoreactivity was detected in cortical sections with a specific primary antibody and an ABC staining kit and visualized with a DAB detection kit (both kits were obtained from Vector Laboratories Inc., Burlingame, CA, USA). Primary antibodies against collagen IV (1:200) and laminin (1:200) were obtained from Abcam. The sections were examined using an Olympus BX43F microscope. Linear measurements were obtained using an image analysis system (Image-Pro Plus 4.0, Media Cybernetics, Silver Spring, MD, USA).

Cell immunofluorescence (IF) Mesangial cells were seeded onto round glass dishes and then subjected to various treatments. After they were washed three times with cold PBS, the cells were fixed with cold methanol at − 20°C for 15 min and then incubated in blocking buffer (1% BSA and 0.1% Triton X-100 in PBS, pH 7.4) for 30 min at room temperature. The cells were subsequently incubated with Nrf2 (1:200), Keap1 (1:100), collagen IV (1:200), and laminin (1:100) primary antibodies for 12 h at room temperature. Then, the cells were washed three times with PBS and incubated with a secondary antibody conjugated to DyLight 594 or DyLight 488 (Earthox, Millbrae, CA, USA) at 37°C for 1 h in the dark. The cell nuclei were stained with DAPI (Beyotime Institute of Biotechnology) for 1 min. Coverslips were mounted onto the glass slides, and the cells were viewed with an Olympus BX43F fluorescence microscope (Tokyo, Japan).

The fluorescent probe 2′,7′-dichlorofluorescin diacetate (DCFH-DA, Sigma) was applied to evaluate the intracellular ROS levels. Cells were grown in six-well plates, and after being treated with different concentrations of AB38b or Res, the cells were incubated with 10 μM DCFH-DA at 37°C for 25 min. Then, the distribution of DCF fluorescence in 10 000 cells was measured by flow cytometry (Miltenyi Biotec, Bergisch Gladbach, Nordrhein-Westfalen, Germany) at an excitation wavelength of 488 and an emission wavelength of 525 nm.

The statistical analysis of the experimental data was performed using SPSS 16.0 software, and the results are presented as the mean ± SD (standard deviation). Statistical differences were determined using analysis of variance followed by Dunnett's test (Exp. versus Con.) using one trial analysis. A significant difference was defined as P < 0.05 compared with the control.

The protective effect of some new compounds on mesangial cells The cytotoxicity of the new compounds in GMCs was investigated by the CCK8 assay. The results indicated that treatment with 10 μM of the compounds for 24 h did not produce any significant cytotoxic effects, whereas 20 μM significantly decreased cell viability (Fig. 1a) . To further evaluate whether the new compounds can protect GMCs against oxidative damage, cell viability was measured. Treatment with 10 μM of the new compounds reduced the cell growth inhibition caused by H 2 O 2 (Fig. 1b) . Given the cytotoxicity of the dose of 20 μM, a dose of 10 μM of the compounds was used to investigate their effects on antioxidant genes. Compared with those of the normal group (NG), the mRNA levels of HO-1, NQO-1, and SOD were increased significantly (Fig. 1c) in the group treated with the compounds, among which AB38b (Fig. 1e) showed excellent antioxidant activity. Treatment with AB38b increased cell viability suppressed by H 2 O 2 in a dose-dependent manner (Fig. 1d) . Therefore, doses of 2.5, 5, and 10 μM AB38b were used in the subsequent experiments to examine its role against OS and its potential ability to protect against DN.

AB38b reversed the alterations in biochemical parameters in diabetic mice The FBG levels, body weight, and kidney weight-to-body weight ratio of the experimental mice were examined. Compared with those of the normal control mice, the FBG levels and the kidney weight-tobody weight ratio of the diabetic mice were significantly increased ( Table 2) . AB38b treatment had no effect on the FBG levels or kidney index of the mice. However, AB38b markedly reduced serum urine nitrogen (BUN, Fig. 2a) , serum creatinine (Cr, Fig. 2b) , LDL-C (Fig. 2c) , and T-CHO (Fig. 2d ) levels in diabetic mice in a dose-dependent manner, and AB38b treatment had no effect on normal control mice, suggesting that AB38b improved renal function in diabetic mice. AB38b reduced ECM deposition and morphological changes in diabetic kidneys PAS staining showed that glycogen deposition was enhanced in diabetic mice compared with control mice; however, this enhancement was alleviated in diabetic mice treated with AB38b (Fig. 3a, f) . Sirius red staining was used to evaluate the severity of renal fibrosis in diabetic mice. Compared with that in normal control mice, the distribution of Sirius red-positive areas was significantly increased in diabetic mice, indicating collagen accumulation in both the glomerular and renal interstitium. The administration of AB38b reduced collagen deposition to different degrees (Fig. 3b, g) . EM revealed that extensive foot process fusion occurred in the kidneys of diabetic mice (Fig. 3c-2 vs. c-1). Moreover, laminin and collagen IV expression, as measured by IHC, was increased in untreated diabetic mice compared with control mice (Fig. 3d-2 vs. d-1 , and e-2 vs. e-1), however, these changes were significantly reversed by AB38b in a dose-dependent manner, and AB38b treatment had no effect on normal mice (Fig. 3d, e, h, i) . These data suggest that AB38b dramatically ameliorates the glomerular damage, foot process fusion, and ECM deposition noted in the kidneys of diabetic mice.

AB38b alleviated OS and concomitantly activated Nrf2 in diabetic mice Compared with those in normal control mice, the levels of MDA and LDH were markedly increased in the kidney cortex of diabetic mice. In contrast, the GSH level and CAT and SOD activities were obviously decreased. Treatment with AB38b effectively reversed these changes (Fig. 4a-e) . The protein and gene expression of Nrf2, NQO-1, and HO-1 in the kidney cortex were examined by western blot and qRT-PCR. Diabetic mice exhibited decreased protein levels of Nrf2, NQO-1, and HO-1 in renal cortex homogenates, whereas the protein levels of Keap1 were obviously increased. These changes were reversed by AB38b in a dosedependent manner (Fig. 4f, j) . The mRNA levels of Nrf2, NQO-1, and HO-1 confirmed these results (Fig. 4k-m) .

To further verify the protective effects of AB38b on OS, HPLC was used to measure the levels of MDA in mesangial cells. Our data showed that MDA was significantly increased in the HG groups. As expected, 5 μM and 10 μM AB38b remarkably decreased the increase in MDA (Fig. 5a ). In addition, AB38b blocked the high levels of LDH induced by HG (Fig. 5b) . GSH activity and SOD levels in the HG group were lower than those of the NG group, whereas treatment with different concentrations of AB38b significantly increased GSH activity and SOD levels ( Fig. 5c-f ). As shown in Fig. 5g , 5 μM and 10 μM AB38b significantly reduced the intracellular ROS in SV40 cells. These results indicate that AB38b can ameliorate OS induced by HG in mesangial cells.

AB38b inhibited HG-induced ECM accumulation while enhancing the expression of Nrf2 and its downstream gene in mesangial cells IF analysis revealed that AB38b exerted an inhibitory effect on the increased laminin and collagen IV expression in the HG group (Fig. 6a, b) , and the effects of AB38b were dosedependent. These advantageous effects paralleled the AB38binduced transcriptional activation of Nrf2. To cope with HGinduced OS, the protein and gene levels of Nrf2, NQO-1, and HO-1 increased in the HG group. However, these changes were small and did not have a major influence on redox status or ECM component synthesis in mesangial cells, whereas treatment with different concentrations of AB38b prominently activated the Nrf2 signaling pathway in HG-treated mesangial cells ( Fig. 7a-g) and reversed the increased expression of laminin and collagen IV (Fig. 6a, b) . IF analysis confirmed these results, and the nuclear import of Nrf2 was further increased after the administration of low, medium, and high doses of AB38b (Fig. 7h, Nrf2 panel) . In addition, AB38b blocked the high levels of Keap1 induced by HG (Fig. 7h, Keap1 panel) . These results imply that AB38b activates Nrf2 by inhibiting the expression of Keap1, ultimately ameliorating OS and ECM accumulation.

Nrf2 was involved in the inhibitory effect of AB38b on ECM accumulation and OS To further confirm the involvement of Nrf2 in the function of AB38b, we detected changes in ECM proteins (collagen IV and laminin) and the activity of antioxidant enzymes, including CAT, GSH, and SOD, in stable Nrf2 knockdown SV40 cells, which were treated with HG and 10 μM AB38b. As shown in Fig. 8a -c, after treatment with 10 μM AB38b, the protein levels of collagen IV and laminin were significantly decreased in HG-induced si-veh SV40 cells, whereas they were increased in HG-induced si-Nrf2 cells. In contrast, the levels of the antioxidant enzymes CAT (Fig. 8d) , GSH (Fig. 8e) and SOD (Fig. 8f) displayed the opposite trends. These results demonstrate that AB38b inhibits ECM accumulation and OS through Nrf2.

AB38b increased Nrf2, probably by inhibiting ubiquitination and degradation To further explore the underlying mechanisms by which AB38b activates Nrf2, mesangial cells were divided into the vehicle control group (DMSO, 0.05%), the medium-dose AB38b group (5 μM), the positive control group (SFN, 2.5 μM), and the proteasome inhibitor group (MG132, 2.5 μM). Compared with those in the DMSO group, the total Nrf2 protein and nucleoprotein levels in mesangial cells were significantly increased in the AB38b group (Fig. 9f, g) , whereas the opposite results were observed for cytosolic Nrf2 expression in the AB38b group (Fig. 9h) , indicating that AB38b can facilitate the nuclear import of Nrf2. The results were similar to those of the SFN group and MG132 group. In addition, total Nrf2 mRNA expression in the AB38b group showed no increase, whereas it slightly increased in the SFN group and MG132 group (Fig. 9b) . In contrast, AB38b remarkably decreased the expression of Keap1. However, SFN and MG132 had no significant effect on Keap1 expression (Fig. 9c-e) . The mRNA level of Keap1 confirmed these results (Fig. 9a) . IP assays utilizing Nrf2 and Keap1 antibodies showed that the interactions between Nrf2 and Keap1 were significantly reduced in mesangial cells treated with SFN; however, there were no such changes in the AB38b group and MG132 group (Fig. 9i) , implying that AB38b facilitates Nrf2 signaling by decreasing Keap1 expression without influencing the interactions between Nrf2 and Keap1.

Furthermore, AB38b, SFN, and MG132 significantly attenuated the activity of the 20 S proteasome (Fig. 9j) , suggesting that AB38b has a key role in blocking the degradation of ubiquitinconjugated proteins in mesangial cells by the 20 S complex. In addition, the ubiquitination of Nrf2 was measured after treatment with AB38b. The levels of ubiquitinated Nrf2 decreased when SV40 cells were treated with AB38b, however, these conjugated proteins significantly accumulated when the cells were incubated with the proteasome inhibitor MG132 (Fig. 9k) . These results suggest that AB38b decreases Nrf2 degradation by inhibiting its ubiquitination.

The overproduction of reactive oxygen species (ROS) and the development of OS are common features of many kidney diseases, including DN [33, 34] . In addition, ROS are recognized as important mediators of several biological responses, including proliferation, ECM deposition, and apoptosis [5] . Increasing evidence has reported that therapies with antioxidant potential have beneficial effects on kidney diseases [35] [36] [37] . Therefore, the application of antioxidant agents against ROS stimulation in DN has attracted increasing attention. AB38b is a novel synthetic α, βunsaturated carbonyl compound with DDB as its precursor. The results presented here indicate that AB38b increases the survival rate of mesangial cells and exerts significant protective effects against H 2 O 2 -induced damage. Considering the protective effects of AB38b in mesangial cells, we hypothesize that AB38b has a protective role in DN by inhibiting OS.

GMCs are the main type of cells that secrete ECM proteins and play a critical role in the progression of DN [38, 39] . Furthermore, it is well known that hyperglycemia is considered the main initiative factor in the progression of DN [40] . Exposure to a HG milieu induces cell proliferation and ECM accumulation in GMCs, ultimately leading to DN [41, 42] . Thus, an in vitro HG model was established in mouse mesangial cells to evaluate the effects of AB38b on OS and ECM accumulation. Our results showed that HG stimulation obviously induced the expression of laminin and collagen IV in GMCs, the main components of the ECM. However, this elevation was abrogated by AB38b treatment in a dose-dependent manner. Similar to the results obtained in vitro, the in vivo study showed increased expression of laminin and collagen IV in the renal cortex of diabetic mice. This result is in line with that of another study in which the caffeamide derivative KS370G was administered to renal ischemia reperfusion injury (IRI) mice and renal tubular epithelial cells (NRK52E and HK-2) to verify its antifibrotic potential. KS370G ameliorated IRI through its ability k The inhibitory effect of AB38b on ubiquitinated Nrf2 in SV40 cells. Total cell lysates were immunoprecipitated with an anti-Nrf2 antibody and then immunoblotted with an anti-ubiquitin antibody. The data are expressed as the mean ± SD, n = 3. *P < 0.05, **P < 0.01 vs. DMSO to significantly reduce the IRI-induced accumulation of ECM proteins (collagen and fibronectin) in mice and in cells [43] . Furthermore, under persistent diabetic conditions, the renal function in these mice worsens significantly and the conventional parameters Cr, BUN, LDL-C, and T-CHO are elevated. However, treatment with AB38b improves these changes induced by diabetes. These results indicate that AB38b is an effective compound for protecting against and alleviating a decline in renal function and renal fibrosis. During periods of hyperglycemia, renal cells fail to attenuate the entrance of glucose into the cell, resulting in increased substrate levels for the mitochondrial electron transport chain, which leads to even more-reactive electron carriers and thus an enhanced production of ROS [44] . It is well known that antioxidant enzymes such as SOD, CAT, and GSH have synergistic roles in the clearance of oxygen free radicals [45] . In addition, MDA is considered the most-representative indicator of oxidative damage because it is a key product of lipid peroxidation [46] . In the current study, we found that GSH, T-SOD, and CAT were downregulated, whereas the MDA accumulated in HG-induced mesangial cells and diabetic mice. However, treatment with AB38b improved these changes, implying that AB38b can maintain the balance of OS under diabetic conditions and plays an important role in antioxidation. It is worth mentioning that the protective effect of a high dose of AB38b (10 μM) on antioxidant enzymes is similar to that of resveratrol. Several other studies are consistent with ours, showing that the antiinflammatory conditions associated with diabetes are ameliorated by antioxidants and their synergistic potentials through the reduction of albumin and MDA [47] [48] [49] .

Therefore, a better understanding of the molecular mechanisms underlying these effects is crucial. We previously observed that Nrf2 is a critical redox sensor and one of the master regulators of the antioxidant response [50, 51] . Nrf2 binds to regulatory AREs and activates the transcription of many antioxidant genes, such as HO-1 and NQO-1, which counteract ROS [52, 53] . To confirm the role of AB38b in the modulation of Nrf2 signaling in DN, real-time PCR, western blot, and IF staining were used to detect mRNA levels, protein expression, the distribution of Nrf2 expression and the levels of key antioxidant genes, including NQO-1 and HO-1. It is known that Nrf2 expression and function in cells (in vitro) are increased in response to OS, and several studies have indicated that HG can elevate Nrf2 expression and activation and the expression of its downstream gene in various cells [54] . Our findings are consistent with those of previous studies showing that HG stimulation obviously induces the nuclear protein levels of Nrf2 and upregulates NQO-1 and HO-1 levels. However, the increase in Nrf2 induced by HG is only a compensatory reaction of the body, and the protective effect of this reaction in cells and tissues cannot prevent the occurrence of DN. Nrf2 adaptively tries to remain functional to remove ROS and overcome diabetic damage in the early stage of diabetes. In the late stage of diabetes, however, antioxidant function is further impaired, leading to a decrease in Nrf2 expression [55, 56] . In agreement with these above studies, our in vivo study indicated that Nrf2 expression was decreased in the DN group compared with the control group. AB38b treatment greatly induced the expression of Nrf2 and its downstream targets NQO-1 and HO-1 in the DN group and control group. The results presented here indicate that AB38b activates Nrf2 signaling and exerts strong antioxidant activity, which may maintain long-term redox equilibrium in cells. Our data agree with another study in which antioxidant carnosol showed a protective antioxidant effect against OS through the activation of a pathway involving HO-1 in rat pheochromocytoma PC12 cells [57] . The oral administration of Protandim, a patented Nrf2 activator, in mdx mice (a mouse model of Duchenne muscular dystrophy) induced Nrf2 and HO-1 upregulation in SU5416/hypoxia-induced pulmonary hypertension and reduced OS in fatal heart disease and diaphragm fibrosis; it was also observed that osteopontin (a prominent biomarker of fibrosis) was reduced significantly. It was therefore concluded that the ability of Protandim to reduce osteopontin and OS may be attributed to its capacity to activate Nrf2/HO-1 signaling [58] .

Several studies have indicated that Nrf2 activators such as resveratrol (Res), sulforaphane (SFN), and MG132 have protective effects against DN. Res can normalize the protein expression of Nrf2 and its downstream genes and has been used to prevent cancer, diabetes, and metabolic diseases, but its mechanism remains incompletely understood [59] [60] [61] . SFN interacts with Keap1 to disrupt Nrf2-Keap1 binding and allows for the nuclear accumulation of Nrf2 [62] . In addition, MG132 has a key role in blocking the degradation of ubiquitin-conjugated proteins by the 26 S complex [63] . Based on the above research status, we chose Res, SFN, and MG132 as positive controls to further explore the efficacy, mechanism and possible target of the AB38b-induced activation of Nrf2. In this study, we found that the protective effect of AB38b against DN and its excitatory effect on Nrf2 are consistent with those of Res. In addition, AB38b treatment greatly suppressed the expression of Keap1 and reduced the ubiquitination of Nrf2. These findings indicate that AB38b induces Nrf2 signaling by downregulating Keap1, suppressing the ubiquitination of Nrf2 and enhancing Nrf2 nuclear translocation.

In summary, our studies provide experimental evidence that AB38b inhibits OS and ECM expression induced by hyperglycemia in DN, at least in part by activating the Keap1/Nrf2 signaling pathway. Therefore, AB38b may be a potential agent for the treatment of DN.

Predictive metabolic signatures for the occurrence and development of diabetic nephropathy and the intervention of Ginkgo biloba leaves extract based on gas or liquid chromatography with mass spectrometry

Protective effects of sarsasapogenin against early stage of diabetic nephropathy in rats

Oxidative stress in diabetic nephropathy with early chronic kidney disease

Non-genetic mechanisms of diabetic nephropathy

Artesunate ameliorates high glucoseinduced rat glomerular mesangial cell injury by suppressing the TLR4/NF-kappaB/ NLRP3 inflammasome pathway

Berberine as a promising anti-diabetic nephropathy drug: an analysis of its effects and mechanisms

Effect of AB38b on diabetic nephropathy via Keap1/Nrf2

Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway

Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy

The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation

Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation

Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection

Low fucose containing bacterial polysaccharide facilitate mitochondria-dependent ROSinduced apoptosis of human lung epithelial carcinoma via controlled regulation of MAPKs-mediated Nrf2/Keap1 homeostasis signaling

Nrf2 possesses a redoxinsensitive nuclear export signal overlapping with the leucine zipper motif

Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases

Nuclear import and export signals in control of Nrf2

Diabetic nephropathy: a disorder of oxygen metabolism?

Neuroprotection of quercetin on central neurons against chronic high glucose through enhancement of Nrf2/ARE/glyoxalase-1 pathway mediated by phosphorylation regulation

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial

Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulointerstitial nephropathy

Sulforaphane attenuation of experimental diabetic nephropathy involves GSK-3 beta/Fyn/Nrf2 signaling pathway

Sulforaphane induces Nrf2 target genes and attenuates inflammatory gene expression in microglia from brain of young adult and aged mice

Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) is a novel therapeutic target for diabetic complications

Regulation of the Keap1/Nrf2 system by chemopreventive sulforaphane: implications of posttranslational modifications

Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl

Diabetic nephropathy: are there new and potentially promising therapies targeting oxygen biology?

Compounds that increase or mimic cyclic adenosine monophosphate enhance tristetraprolin degradation in lipopolysaccharide-treated murine j774 macrophages

Chemopreventive effect of dimethyl dicarboxylate biphenyl on malignant transformation of WB-F344 rat liver epithelial cells

Protective role of dimethyl diphenyl bicarboxylate (DDB) against erythromycin induced hepatotoxicity in male rats

The effect of dimethyl dimethoxy biphenyl dicarboxylate (DDB) against tamoxifen-induced liver injury in rats: DDB use is curative or protective

Curcumin attenuates Nrf2 signaling defect, oxidative stress in muscle and glucose intolerance in high fat diet-fed mice

The mTOR promotes oxidative stress-induced apoptosis of mesangial cells in diabetic nephropathy

Quercetin inhibits the mTORC1/p70S6K signaling-mediated renal tubular epithelial-mesenchymal transition and renal fibrosis in diabetic nephropathy

Reactive oxygen species-regulated signaling pathways in diabetic nephropathy

Oxidative stress and vascular inflammation in aging

6-Shogaol ameliorates diabetic nephropathy through anti-inflammatory, hyperlipidemic, anti-oxidative activity in db/db mice

Salidroside alleviates high glucose-induced oxidative stress and extracellular matrix accumulation in rat glomerular mesangial cells by the TXNIP-NLRP3 inflammasome pathway

Nephroprotective effect of Paeonia emodi via inhibition of advanced glycation end products and oxidative stress in streptozotocinnicotinamide induced diabetic nephropathy

Morin inhibits cell proliferation and fibronectin accumulation in rat glomerular mesangial cells cultured under high glucose condition

High glucose induces rat mesangial cells proliferation and MCP-1 expression via ROS-mediated activation of NF-kappaB pathway, which is inhibited by eleutheroside E

The pathobiology of diabetic complications: a unifying mechanism

Cellular and molecular mechanisms of vascular injury in diabetes-part I: pathways of vascular disease in diabetes

Diabetic nephropathy and extracellular matrix

Effects of free anthraquinones extract from the Rhubarb on cell proliferation and accumulation of extracellular matrix in high glucose cultured-mesangial cells

The role of reactive oxygen species in apoptosis of the diabetic kidney

Lens superoxide dismutase and catalase activities in diabetic cataract

In vitro glucoseinduced cataract in copper-zinc superoxide dismutase null mice

Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes

Antioxidants in kidney diseases: the impact of bardoxolone methyl

Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial

Adaptive induction of NF-E2-related factor-2-driven antioxidant genes in endothelial cells in response to hyperglycemia

Oxidative stress and Nrf2 in the pathophysiology of diabetic neuropathy: old perspective with a new angle

Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy

Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo

Nrf2 activators modulate oxidative stress responses and bioenergetic profiles of conditions

The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy

Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes

Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol

Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation

High glucose induces renal mesangial cell proliferation and fibronectin expression through JNK/NF-kappaB/ NADPH oxidase/ROS pathway, which is inhibited by resveratrol

Resveratrol represses estrogen-induced mammary carcinogenesis through NRF2-UGT1A8-estrogen metabolic axis activation

Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling

SNrf2 and NF-kappaB modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes

Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome

XXY, QL, LD, LW, and MH contributed to the study design, manuscript preparation, and drafting of the manuscript. LW, LD, JW, MH, YBC, XZL, CCL, YL, and HY contributed to data collection, analysis, and revising the manuscript for important content. XKG and YFJ designed, synthesized, and analyzed the chemical compounds. All authors read and approved the final manuscript.

Competing interests: The authors declare no competing interests.